20/02/2004
Charity hails potential breakthrough to cancer treatment
Stripping cancer cells of their defences against chemotherapy with a new class of anti-resistance drug has the potential to improve treatment for many solid tumours, Cancer Research UK scientists have said.
Cancer cells often resist the effects of treatment with the help of a molecule called P-glycoprotein, which acts as a molecular bouncer – throwing out anti-cancer drugs before they get a chance to take action. But in a study published in the March edition of the European Journal of Cancer, researchers in Oxford have stated that they were able to inactivate the ejection mechanism, making cancer cells vulnerable to treatment.
Scientists knew that a drug called XR9576 could block P-glycoprotein and sensitise individual cancer cells to chemotherapy, but they did not know if the drug would be successful against whole tumours, which can be very difficult to treat.
Professor Robert Souhami, Cancer Research UK, Director of Clinical and External Affairs, said: "It's very upsetting when a patient whose tumour initially seemed to be responding to chemotherapy then begins to relapse as cells become resistant to treatment.
"Cancer cells use a number of strategies for avoiding the effects of chemotherapy, but we can develop methods to overcome them. The new study has demonstrated that by overpowering one of the molecular doormen that many cancer cells employ, it is possible to leave tumours vulnerable to treatment once more. This has obvious potential implications for treatment."
In tests the anti-resistance drugs managed to keep cancer at bay for several years, and some of the most progressive cancers were stalled for several months using the therapy.
Doctor have given the research a cautious welcome.
(gmcg)
Cancer cells often resist the effects of treatment with the help of a molecule called P-glycoprotein, which acts as a molecular bouncer – throwing out anti-cancer drugs before they get a chance to take action. But in a study published in the March edition of the European Journal of Cancer, researchers in Oxford have stated that they were able to inactivate the ejection mechanism, making cancer cells vulnerable to treatment.
Scientists knew that a drug called XR9576 could block P-glycoprotein and sensitise individual cancer cells to chemotherapy, but they did not know if the drug would be successful against whole tumours, which can be very difficult to treat.
Professor Robert Souhami, Cancer Research UK, Director of Clinical and External Affairs, said: "It's very upsetting when a patient whose tumour initially seemed to be responding to chemotherapy then begins to relapse as cells become resistant to treatment.
"Cancer cells use a number of strategies for avoiding the effects of chemotherapy, but we can develop methods to overcome them. The new study has demonstrated that by overpowering one of the molecular doormen that many cancer cells employ, it is possible to leave tumours vulnerable to treatment once more. This has obvious potential implications for treatment."
In tests the anti-resistance drugs managed to keep cancer at bay for several years, and some of the most progressive cancers were stalled for several months using the therapy.
Doctor have given the research a cautious welcome.
(gmcg)
Related UK National News Stories
Click here for the latest headlines.
17 June 2005
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
25 March 2014
Cancer Research UK Raises Over £8m In Six Days
Cancer Research UK has raised over £8 million in donations in just six days thanks to the #nomakeupselfie trend. The #nomakeupselfie trend isn't something Cancer Research UK started.
Cancer Research UK Raises Over £8m In Six Days
Cancer Research UK has raised over £8 million in donations in just six days thanks to the #nomakeupselfie trend. The #nomakeupselfie trend isn't something Cancer Research UK started.
26 September 2003
Genetic testing could assist in cancer treatment, report claims
Testing tumours for the breast cancer gene BRCA1 could be a powerful way of predicting how patients will respond to chemotherapy, scientists from Breast Cancer Campaign and Cancer Research UK have said. Researchers have found that tumour cells react differently to chemotherapy depending on how well BRCA1 is working within them.
Genetic testing could assist in cancer treatment, report claims
Testing tumours for the breast cancer gene BRCA1 could be a powerful way of predicting how patients will respond to chemotherapy, scientists from Breast Cancer Campaign and Cancer Research UK have said. Researchers have found that tumour cells react differently to chemotherapy depending on how well BRCA1 is working within them.
08 August 2011
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
17 October 2005
Breast cancer can cost ‘thousands’
Breast cancer can cost sufferers thousands of pounds, a survey by a leading cancer charity has revealed. Macmillan Cancer Relief surveyed 50 cancer patients and found that, on average, they spent almost £2,000 on extra costs during their treatment.
Breast cancer can cost ‘thousands’
Breast cancer can cost sufferers thousands of pounds, a survey by a leading cancer charity has revealed. Macmillan Cancer Relief surveyed 50 cancer patients and found that, on average, they spent almost £2,000 on extra costs during their treatment.